Program

SESSION 1: MOLECULAR AND CELLULAR MECHANISMS REGULATING T-CELL FUNCTION IN CANCER

Chairperson: Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA
7:00 p.m.-9:00 p.m.

Endothelial Regulation of T cell Homing to Tumors
George Coukos, University of Pennsylvania, Philadelphia, PA

Correcting the Anergy of Human Tumor-infiltrating Lymphocytes
Pierre van der Bruggen, Ludwig Institute for Cancer Research, Brussels, Belgium

KEYNOTE LECTURE

T Cell Receptors, MHC, and Tumor Antigens
Philippa Marrack, National Jewish Medical and Research Center and the Howard Hughes Medical Institute, Denver, CO

OPENING RECEPTION

9:00 p.m.-10:00 p.m.

SESSION 2: TUMOR ANTIGENS AND MECHANISMS OF IMMUNE SURVEILLANCE

Chairperson: Alexander M. M. Eggermont, Erasmus University Rotterdam, Rotterdam, The Netherlands
8:30 a.m.-10:30 a.m.

Immune Memory for Abnormal Self Antigens in Cancer Immunosurveillance
Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA

Telomerase Vaccination and Treg Modulation
Robert H. Vonderheide, Abramson Cancer Center, Philadelphia, PA

Naturally-acquired and Vaccine-induced CD8 T cell Immunity to Tumor-associated Antigens in Advanced Melanoma Patients
Pedro Romero, Ludwig Institute, Lausanne, Switzerland

* Cancer Mucosa Antigens are Novel Immunological Targets for Tumor Therapy
Adam Snook, Thomas Jefferson University, Philadelphia, PA

* Altered Expression of 15-Hydroxyprostaglandin Dehydrogenase in Intra-Tumoral CD11b Myeloid Cells: A Mechanism for Immune Evasion in Cancer
Evgeniy Eruslanov, University of Florida College of Medicine, Gainesville, FL

SESSION 3: ANTIBODIES IN CANCER IMMUNOTHERAPY

Chairperson: Louis M. Weiner, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC
10:30 a.m.-12:30 p.m.

Tumor Targeting Antibodies from Phage and Yeast Libraries
James D. Marks, University of California, San Francisco, CA

Anti-tumor Antibodies: Conversion of Passive to Active Immunity
Raphael Clynes, Columbia University, New York, NY

Tumor Targeting: Theory and Experiment
K. Dane Wittrup, Massachusetts Institute of Technology, Cambridge, MA

* A Monoclonal Antibody against CD47 Eradicates Human Acute Myeloid Leukemia by Blocking a Mechanism of Immune Evasion
Mark P. Chao, Stanford University, East Palo Alto, CA

* Anti-CD20 Ige: A Novel Antibody for the Treatment of Non-Hodgkin's Lymphoma
Gustavo Helguera, University of California, Los Angeles, CA

SESSION 4: WORKSHOP

Chairperson: Kavita Dhodapkar, The Rockefeller University, New York, NY
2:30 p.m.-4:30 p.m.

Targeting Fcgamma Receptors on Dendritic Cells to Regulate Tumor Immunity
Kavita Dhodapkar

* Tumor Vaccination Revisited: Ineffective Vaccination against Established Metastatic Colon Tumors Can Be Enhanced by Hematopoetic Cell Transplantation
Alexander Filatenkov, Stanford University, Stanford, CA

* Induction of Objective Clinical Responses in the Majority of Patients with an HPV16-Induced High-Grade Premalignant Lesion of the Vulva by Therapeutic Vaccination
Sjoerd van der Burg, Leiden University Medical Center, Leiden, The Netherlands

* B7-DC-Fc (AMP-224), a Novel Co-Stimulatory Therapeutic, Induces Tumor Regression and Long Term Immune Protection in Multiple Mouse Models
Linda N. Liu, Amplimmune, Inc., Rockville, MD

* Modulation of both NK Receptors and Their Corresponding Ligands with Histone Deacetylase Inhibitors and Proteasome Inhibitors
Shiguo Zhu, UT M. D. Anderson Cancer Center, Houston, TX

* Systemic CD40 Activation Modulates the Tumor Microenvironment in a Genetically-Engineered Model of Pancreatic Adenocarcinoma: Implications for Novel Cancer Immunotherapy
Gregory L. Beatty, University of Pennsylvania, Philadelphia, PA

* A Novel Role for Tyrosine Kinase Inhibitor in the Reversal of Immune Tolerance and Modulation of the Tumor Microenvironment in Immune-Based Therapies
Shu-Hsia Chen, Mount Sinai School of Medicine, New York, NY

* Dicer-regulated Micro RNAs 222 and 339 Promote Immune-Escape of Cancer Cells Through Downregulation of ICAM-1
Hideho Okada, University of Pittsburgh Cancer Center, Pittsburgh, PA

POSTER SESSION A

4:30 p.m.-6:30 p.m.

SESSION 5: REGULATION OF TUMOR GROWTH BY TUMOR MICROENVIRONMENT

Chairperson: Suzanne Ostrand-Rosenberg, University of Maryland, Baltimore, MD
8:00 a.m.-10:00 a.m.

Tumor-induced Immune Suppression: The Inflammation Connection and New Tricks for Suppressing Anti-tumor Immunity
Suzanne Ostrand-Rosenberg

Destruction of the Stromal Tumor Microenvironment by T cells
Hans Schreiber, University of Chicago, Chicago, IL

Tissue-specific Mechanisms Regulate Pro-tumor Immunity
Lisa M. Coussens, UCSF Comprehensive Cancer Center and Cancer Research Institute, San Francisco, CA

* IDO Is an Integral Component of Chronic Inflammation Critical to Supporting Tumorigenesis
Alexander J. Muller, Lankenau Institute for Medical Research, Wynnewood, PA

* Tumor-Targeted Delivery of CpG and STAT3 Inhibitor JSI-124 Using Poly(D,L-lactic-co-glycolic acid) (PLGA) Nanoparticles to Modulate Tumor Immunosuppressive Environment
Ommoleila Molavi, University of Alberta, Edmonton, AB, Canada

SESSION 6: EPIGENETIC REGULATION OF TUMOR GROWTH AND IMMUNE RECOGNITION

Chairperson: Louis M. Staudt, National Cancer Institute, Bethesda, MD
10:30 a.m.-12:30 p.m.

FOXP3 and Cancer
Yang Liu, University of Michigan, Ann Arbor, MI

Signatures of the Tumor Microenvironment Predict Survival in Lymphoma
Louis M. Staudt

Transcription Factors and Tumor Vaccines
Jenny P-Y. Ting, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

* Glioma Cancer Stem Cells Mediate Immune Suppression That Can Be Reversed with p-STAT3 Blockade
Jun Wei, UT M. D. Anderson Cancer Center, Houston, TX

* IL17 Enhances Tumor Growth in vitro and in vivo
Dori A. Thomas, Abbott Laboratories, Abbott Park, IL

POSTER SESSION B

12:30 p.m.-2:30 p.m.

SESSION 7: NEW ADVANCES IN THE DEVELOPMENT OF CANCER VACCINES

Chairperson: John H. Sampson, Duke University Medical Center, Durham, NC
6:00 p.m.-8:30 p.m.

New Advances in the Development of Cancer Vaccines
John H. Sampson

Vaccines, Immune Checkpoints, and Pancreatic Cancer
Elizabeth M. Jaffee, Johns Hopkins Oncology, Baltimore, MD

The Development of Immunoregulatory Antibodies for Cancer
Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa, FL

Which Patients Should We Target for Vaccine Development in Melanoma?
Alexander M. M. Eggermont, Erasmus University Rotterdam, Rotterdam, The Netherlands

SESSION 8: CO-STIMULATION AND IMMUNE SUPPRESSION IN CANCER - A TWO-FACED JANUS

Chairperson: Drew M. Pardoll, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
8:00 a.m.-10:00 a.m.

Mechanisms of B7-H1 in the Evasion of Tumor Immunity
Lieping Chen, Johns Hopkins University, Baltimore, MD

Immune Regulation from Within the Tumor Microenvironment
Thomas F. Gajewski, University of Chicago, Chicago, IL

Therapeutic Modulation of Co-stimulation and Co-inhibition
Drew M. Pardoll

* OX40 Inhibits Treg Suppression on DC and Bridges Treg Interaction with Mast Cells
Mario Colombo, Istituto Nazionale Tumori, Milano, Italy

* A Role for Antigen Presenting Cells in the Tolerization of Tumor-Specific T Cells
Arthur Hurwitz, National Cancer Institute, Frederick, MD

SESSION 9: IMMUNE SUPPRESSION MEDIATED BY MYELOID CELLS

Chairperson: Dmitry I. Gabrilovich, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
10:30 a.m.-12:30 p.m.

Regulation of Tumor Immunity by Myeloid-derived Suppressor Cells
Dmitry I. Gabrilovich

Learning Tolerance from Cancer: The Lesson of Myeloid-Dependent Suppression
Vincenzo Bronte, Istituto Oncologico Veneto, Padova, Italy

Mast Cell Regulation of Acquired Immunity to Tumors
Randolph J. Noelle, Dartmouth College, Hanover, NH

* Polarization of Tumor-Associated Neutrophil (TAN) Phenotype by TGF-β: "N1" versus "N2" TAN- a New Paradigm?
Zvi G. Fridlender, University of Pennsylvania, Philadelphia, PA

* Myeloid-derived Suppressor Cells Inhibit T Cell Activation by Depleting Cystine and Cysteine
Minu Srivastava, University of Maryland, Baltimore County, Baltimore, MD

CLOSING REMARKS

12:30 p.m.-12:45 p.m.

DEPARTURE